淋巴结病理分级策略:IASLC浸润性肺腺癌分级系统背景下的亚洲患者回顾性队列研究
该研究回顾性分析2011至2021年3150例浸润性肺腺癌患者,按N分期分层并依据转移淋巴结病理分级及数量定义mLN GRADE。高mLN GRADE与原发灶病理分级更高、p-TNM分期更高及不同N分期患者更差的无复发生存期相关,且为N1和N2亚组RFS的独立不良预后因素。mLN GRADE可能补充当前N描述符。
要点
- 高mLN GRADE与更差RFS相关,且在N1和N2亚组均为独立预后因素
- N1患者中高mLN GRADE与更高EGFR突变率相关,N2患者中未观察到此关联
- mLN GRADE可能作为当前N分期的补充指标
核心结论
- 高mLN GRADE与不同N分期患者更差的无复发生存期显著相关。
- mLN GRADE可能有助于补充当前N描述符。
研究设计与样本
- 回顾性队列研究,纳入2011至2021年3150例浸润性肺腺癌患者。
- 按N分期分类,并依据每个转移淋巴结的病理分级及转移淋巴结数量进行mLN GRADE分层。
- 采用生存分析揭示mLN GRADE与长期结局的关联。
主要发现
- N分类间总生存期和无复发生存期差异显著(N=3150)。
- 高mLN GRADE与原发肿瘤更高病理分级显著相关(p<0.001)。
- 高mLN GRADE与更高p-TNM分期相关(p=0.008)。
- 高mLN GRADE与不同N分期患者更差RFS相关。
- N1患者中高mLN GRADE与更高EGFR突变率相关(p=0.021),N2患者中无此关联。
临床怎么用
- 在N1和N2肺腺癌患者中评估转移淋巴结病理分级(mLN GRADE)以辅助预后分层。
- mLN GRADE可作为当前N分期的补充信息用于风险判断。
局限性
- 回顾性队列研究设计。
- 研究人群为亚洲患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: International Association for the Study of Lung Cancer grading system has demonstrated the prognostic value of pathologic patterns in primary tumors, establishing a benchmark for survival outcomes. However, whether there is a potential grading system for metastatic lymph nodes (mLNs) to predict outcomes remains unknown. METHODS: From 2011 to 2021, a large cohort of 3150 patients with invasive lung adenocarcinoma was retrospectively analyzed and classified according to their N stages. Patients were further stratified according to different pathologic grades for each mLN as well as the quantity of mLNs, which was named mLN GRADE. Survival analysis was performed to reveal the association between mLN GRADE and long-term outcomes. RESULTS: The prognostic differences between N categories were substantial in terms of both overall survival and recurrence-free survival (RFS) (N = 3150). High mLN GRADE was robustly correlated with a higher pathologic grade (p < 0.001) in primary tumors, a higher p-TNM stage (p = 0.008), and worse RFS in patients with different N stages. High mLN GRADE was linked to a higher epidermal growth factor receptor (EGFR) mutation rate (p = 0.021) in N1 patients, but not in N2 patients. When patients were further stratified by N stage, multivariate analysis identified high mLN GRADE as an independent prognostic factor for worse RFS in both N1 and N2 subgroups. CONCLUSIONS: High mLN GRADE is significantly associated with worse RFS in patients with different N stages. mLN GRADE may help to supplement the current N descriptor. CLINICAL TRIAL INFORMATION: NCT06745830.
引用
- Zhu W, Deng C, Wang Y, et al. Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma - A Retrospective Cohort Study Among Asian Patients. J Thorac Oncol. 2026. PMID: 42697511. doi:10.1016/j.jtho.2026.104184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。